Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 15/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.51 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.49 |
| ▸ | METAP2 | P50579 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14498267 | 1.00 | KCNA5 (0.72) | KCNA5KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL5070604 | 0.86 | KCNA5 (0.71) | KCNA5KCNK3METAP2 | |
| SCHEMBL14301394 | 0.86 | KCNA5 (0.71) | KCNA5KCNK3METAP2 | |
| SCHEMBL14267601 | 0.84 | KCNA5 (1.00) | KCNA5KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL5074801 | 0.82 | KCNA5 (1.00) | KCNA5ALDH1A1HPGD | |
| SCHEMBL5615965 | 0.82 | KCNA5 (1.00) | KCNA5ALDH1A1HPGD | |
| SCHEMBL5072331 | 0.82 | KCNA5 (1.00) | KCNA5ALDH1A1HPGD | |
| SCHEMBL12201554 | 0.80 | KCNA5 (1.00) | KCNA5KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL14267608 | 0.80 | KCNA5 (1.00) | KCNA5KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL14267642 | 0.79 | KCNA5 (0.85) | KCNA5KDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399423-B9 | ANTHRANILIC ACID AMIDES WITH A HETEROARYLSULFONYL SIDE CHAIN, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS A MEDICAMENT OR DIAGNOSTIC AGENT AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-02-27 | — | — | EP | disclosed |
| EP-1399423-B1 | ANTHRANILIC ACID AMIDES WITH A HETEROARYLSULFONYL SIDE CHAIN, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS A MEDICAMENT OR DIAGNOSTIC AGENT AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-11-14 | — | — | EP | disclosed |
| US-7235664-B2 | Anthranilamides with heteroarylsulfonyl side chain, process of preparation, and use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-26 | — | — | US | disclosed |
| US-20050137200-A1 | Potassium channel modulators; antiarrhythmia agents | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-23 | — | — | US | disclosed |
| US-6903216-B2 | Anthranilamides with heteroarylsulfonyl side chain, process of preparation, and use | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-07 | — | — | US | disclosed |
| EP-1399423-A2 | ANTHRANILIC ACID AMIDES WITH A HETEROARYLSULFONYL SIDE CHAIN, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS A MEDICAMENT OR DIAGNOSTIC AGENT AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS | Aventis Pharma Deutschland GmbH (DE) | 2004-03-24 | — | — | EP | disclosed |
| US-20030114499-A1 | Anthranilamides with heteroarylsulfonyl side chain, process of preparation, and use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-06-19 | — | — | US | disclosed |
| WO-2002100825-A2 | ANTHRANILIC ACID AMIDES WITH A HETEROARYLSULFONYL SIDE CHAIN, AND USE THEREOF AS ANTIARRHYTHMIC ACTIVE SUBSTANCES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137200-A1 | Potassium channel modulators; antiarrhythmia agents | KCNJ2, KCNQ5, KCNH1 | KCNA5 6/4885KDM4E 221/4885ALDH1A1 1867/4885 |
| US-20030114499-A1 | Anthranilamides with heteroarylsulfonyl side chain, process of preparation, and use | KCNJ2, KCNQ5, KCNH1 | KCNA5 6/4885KDM4E 261/4885ALDH1A1 1650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.